Last reviewed · How we verify

NCT04659642

Attenuation of Airway and Cardiovascular Responses to Extubation in Chronic Smokers

Status unknown EARLY_PHASE1 Last updated 10 March 2021
What this trial tests

EARLY_PHASE1 trial testing Dexmedetomidine Injection [Precedex] in Airway Responses in 66 participants. Status unknown.

Timeline
30 November 2020
Primary endpoint
6 March 2021
20 March 2021

Quick facts

Lead sponsorNational Cancer Institute, Egypt
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment66
Start date30 November 2020
Primary completion6 March 2021
Estimated completion20 March 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute, Egypt

Who can join

Adults 20 to 60, male only, with Airway Responses or Hemodynamic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this blind comparative study was to compare the effects of dexmedetomidine, fentanyl and their combination on airway reflexes and hemodynamic responses to tracheal extubation in Adult chronic male smoking patients scheduled for abdominal surgeries (of average 2-3 hours duration).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexmedetomidine Injection [Precedex]

Trials testing the same drug.

Other National Cancer Institute, Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing